Sunshine Net Income Applicable To Common Shares from 2010 to 2026
| SBFM Stock | USD 1.17 0.01 0.85% |
Net Loss | First Reported 2016-12-31 | Previous Quarter -902.1 K | Current Value -902.1 K | Quarterly Volatility 1.4 M |
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 9.6 K, Other Operating Expenses of 49.1 M or Total Operating Expenses of 19.9 M, as well as many indicators such as Price To Sales Ratio of 0.066, Dividend Yield of 0.0 or PTB Ratio of 0.0979. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
Sunshine | Net Income Applicable To Common Shares | Build AI portfolio with Sunshine Stock |
Evaluating Sunshine Biopharma's Net Income Applicable To Common Shares across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Sunshine Biopharma's fundamental strength.
Latest Sunshine Biopharma's Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Sunshine Biopharma over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Sunshine Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Sunshine Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (9,664,516) | |
| Coefficient Of Variation | (112.00) | |
| Mean Deviation | 9,602,255 | |
| Median | (2,491,483) | |
| Standard Deviation | 10,824,226 | |
| Sample Variance | 117.2T | |
| Range | 25.7M | |
| R-Value | (0.81) | |
| Mean Square Error | 42.2T | |
| R-Squared | 0.66 | |
| Significance | 0.000071 | |
| Slope | (1,744,163) | |
| Total Sum of Squares | 1874.6T |
Sunshine Net Income Applicable To Common Shares History
About Sunshine Biopharma Financial Statements
Sunshine Biopharma investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how Sunshine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -24.1 M | -22.9 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Sunshine Biopharma Correlation against competitors. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Will Biotechnology sector continue expanding? Could Sunshine diversify its offerings? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sunshine Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (15.02) | Revenue Per Share | Quarterly Revenue Growth 0.012 | Return On Assets | Return On Equity |
Investors evaluate Sunshine Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sunshine Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sunshine Biopharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sunshine Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.